BioCentury
ARTICLE | Strategy

Shire Early and Late

Shire's Movetis acquisition, new venture fund underpin two-armed growth strategy

August 9, 2010 7:00 AM UTC

Shire plc's proposed acquisition of Movetis N.V. fits one arm of the company's growth strategy by acquiring near-to-market or marketed products for specialty indications.

At the same time, Shire is looking to underpin its second arm, which has used acquisitions to build a platform of earlier stage niche products, by putting some $50 million into a new venture vehicle that will make small equity investments in early stage biotechs that could provide growth opportunities in the long term...